The conventional rescue medicine for hypoglycemia is an intramuscular injection of glucagon which must be reconstituted at point of use. This case study describes a collaborative drug repurposing project with Aptar Pharma culminating in the development of a glucagon nasal powder, an easier to administer alternative. The product utilizes Aptar Pharma’s patented Unidose Powder (UDS) System, is easy-to-store, and has a shelf-life of two years from manufacture. It provides diabetes patients with a highly effective rescue medicine that can be administered by a range of potential carers. Success rates with the nasal powder have been shown to exceed those with injectable glucagon and the product’s market value is expected to exceed $150 million by 2025.